Julian C.
- Country
- Germany
- Department
- Neurologische Klinik
Research Overview
- Evaluation of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) in Dementia-Related Morbidity Outcomes
- Randomized, Double‑Blind, Placebo‑Controlled Trial of Intrathecal BIIB080 in Adults 50–80 y with MCI due to Alzheimer’s Disease or Mild AD Dementia
- Phase 2 Randomized Double-Blind Placebo-Controlled Study of VHB937 in Amyotrophic Lateral Sclerosis Patients Over 40 Weeks with Open-Label Extension
Data & Insights
Has run more than one trial at 15 of 106 partner sites.
Specializations
Neurodegenerative Disorders
The investigator specializes in treating and researching progressive neurological conditions, with particular emphasis on Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (AD).
- ALS Treatment Innovation
- Cognitive Decline Management
- Neurological Disease Progression
Their work includes evaluation of innovative therapeutic approaches for both motor neuron and cognitive disorders.
Cognitive Health
Focus areas include the treatment of Mild Cognitive Impairment and various stages of Alzheimer's Disease Dementia, particularly in patients aged 50 to 80 years.
- Early Stage Intervention
- Cognitive Function Assessment
- Dementia Management
Clinical expertise extends to evaluating cognitive decline progression and therapeutic responses in neurodegenerative conditions.
Therapeutic Assessment
Specialized in evaluating treatments for neurological conditions, including assessment of ventilation-free survival in ALS patients and cognitive function measurements in AD patients.
- Disease Progression Monitoring
- Clinical Outcome Measures
- Treatment Response Assessment
Expertise in measuring therapeutic efficacy through validated clinical assessment tools and survival metrics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.